Helix BioPharma Corp. a clinical-stage biopharmaceutical company developing therapies in the field of immune-oncology in Canada. Its product pipeline comprises L-DOS47, a clinical-stage antibody-enzyme conjugate (AEC) that neutralizes the microenvironment of solid tumors; LDOS001, which is in phase I clinical trial to treat non-small cell lung cancer; LDOS002, which is in phase I/II clinical trial for the treatment of non-small cell lung cancer; LDOS003, which is in phase II clinical trial to treat non-small cell lung cancer; LDOS006, which is in phase Ib/II for the treatment of pancreatic cancer; LDOS007, which is in phase Ib/II for the treatment of lung cancer; and CEACAM6-targeting technology, provides multi-specific antibody-drug conjugates (ADCs) for gastrointestinal cancers and radioligand therapeutics for pancreatic cancer. It has collaboration agreements with Moffitt Cancer Center to investigate and determine the benefits of combining L-DOS47 with immune checkpoint inhibitors; and with University Hospital Tuebingen to investigate the effects of L DOS47 on tumor acidity using imaging technologies. The company has an agreement with metaShape Pharma AG for covering LEUMUNA, within the field of adipose tissue-related and metabolic diseases; and GEMCEDA, an oral gemcitabine prodrug combined with cedazuridine in preclinical development for the treatment of solid tumors. Helix BioPharma Corp. was incorporated in 2008 and is headquartered in Vancouver, Canada.…
Helix BioPharma Corp. Announces Fiscal 2026 Year-End Results
Helix BioPharma (TSE: HBP) is listed on the Toronto Stock Exchange, where its shares trade in CAD. It belongs to the Biotechnology industry, part of the Healthcare sector.
The shares were at 0.9000 CAD on 19 November 2026, down 62.5% over 52 weeks. Its 52-week range is 0.7500 CAD to 2.610 CAD: the price is 65.5% below the high and 20.0% above the low.
Its market capitalisation is 68.74M CAD.
Helix BioPharma reports return on equity of -23.6% and an operating margin of 0.0%.
Its debt exceeds its cash by 3.35M CAD, a debt-to-equity ratio of 0.29. Its Piotroski F-score is 0 out of 9, a weak reading of its financial health. The next earnings report is expected on 10 December 2026.